Money Morning LIVE celebrated its first anniversary with a look back at the past year and a special trading strategy session with the hosts.
how to invest
- Watch Money Morning LIVE’s “World’s Biggest Show”
- Stash vs. Robinhood: The Definitive Review
- 10 Best Investment Apps That Aren’t Robinhood
- How Broker Fees Crush Your Profits, and What to Do About It
- How to Invest After the Election
- Personal Finance Tips for Successful Money Management
- Forex Trading Tips for 2016
- Investing for Beginners: A Guide for the New Investor
- A Real Estate Investing Update for 2016
- How to Add 326% to Your Portfolio Ahead of the Fed's Next Press Conference
- How to Invest for Big Profits When the Smartest Guys in the Room Are Wrong
- Profit from 2016 IPOs with These Two "Icebreakers"
- How to Protect Your Biotech Profits from This Legal Limbo
- The Best "Investment" to Protect Your Money Right Now
- The Ultimate Must-Have Investment
- How You Can Beat Wall Street in 15 Simple Steps
Traders, from the most casual to the most serious, are piling into investing apps.
Robinhood and Stash have been two of the biggest winners over the last year.
The Robinhood app alone added 3 million new users in the first quarter of 2020.
But which is better? We'll show you which comes out ahead in the Stash v.
Swarms of new investors jumped into the market in the first quarter of 2020.
Mobile investment apps grew their new accounts by as much as 170%.
Whether you're a new or experienced investor, there's probably a platform for you.
Robinhood is among the best.
But there could be one or two with tools better suited for where you are in your investing career.
Let's look at some of the best investment apps that aren't Robinhood.
Many investors don't give much thought to broker fees, but they should.
Depending on your personal situation, broker fees could be draining as much as one-third of your long-term profits. You can minimize fees with strategies like using a discount broker, but no investor can eliminate them completely.
But there's something more you can do to claw back some of your lost profits.
After correctly predicting the post-election market rally, our expert shares how to invest under a Trump presidency, including which market segments to watch now.
We talked to an expert in personal finance tips to get the best insight on what people are doing wrong, so you can avoid these pitfalls.
The sooner you read this, the sooner you'll put yourself on a path to financial freedom.
Get some top-notch forex trading tips from someone who has worked hard to become very successful with it.
Learn about investing for beginners the right way.
That means you won’t lose money on typical mistakes that new investors make.
Real estate investing requires lots of research. So to get you started, we have an interview here with someone who has been following these markets for years.
After yet more lackluster economic data and the dovish tone from the Fed's April meeting, many investors are anxious about where markets are going next.
Central banks keep expecting old tricks to produce new results. It's not working - money isn't flowing to consumers like they want.
Yes, there's been a low volume of 2016 IPOs due to broader market volatility.
But the IPO market is about to stage a massive turnaround.
Gilead Sciences Inc.'s Sovaldi was a real breakthrough in the fight against the chronic liver disease hepatitis C (HCV). The condition may show no symptoms for years after initial infection but can slowly become debilitating.
Hepatitis C affects as many as 200 million people worldwide, and before Sovaldi, the approved drug regimen could treat only about 50% of cases and could cause serious side effects. Treatment was generally long - 24 to 48 weeks - and arduous.
Sovaldi, on the other hand, could cure more than 90% of cases in a matter of weeks at a cost, in the United States, of around $94,000. The pricing caused controversy, but the drug proved transformative for HCV patients, their families, and doctors.
Sovaldi also proved a huge windfall for investors when it received FDA approval in 2013 and entered the pharmaceutical marketplace the following year.
So far, Gilead shareholders have seen a 2:1 split, several dividend payouts, and gains of more than 155% since 2013. Sales of Sovaldi and Gilead's other HCV drug, Harvoni, topped $12.5 billion in 2015 alone.
Today I have a recommendation for you that's nothing but positive - the best "investment" to protect your money right now.
The securities I'm about to discuss are far safer than the bank. They're extremely liquid.
The "ultimate must-have investment" is a profit play that, when executed correctly, can't fail, but not one in a million investors has thought about it, let alone knows how to play it for maximum profits.
The situation is so lopsided, in fact, that I'd venture a guess that 99.99% of all investors could quadruple their allocation to this particular must-have opportunity and still not have enough.